2243-58-5Relevant articles and documents
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
Haffner, Curt D.,Charnley, Adam K.,Aquino, Christopher J.,Casillas, Linda,Convery, Máire A.,Cox, Julie A.,Elban, Mark A.,Goodwin, Nicole C.,Gough, Peter J.,Haile, Pamela A.,Hughes, Terry V.,Knapp-Reed, Beth,Kreatsoulas, Constantine,Lakdawala, Ami S.,Li, Huijie,Lian, Yiqian,Lipshutz, David,Mehlmann, John F.,Ouellette, Michael,Romano, Joseph,Shewchuk, Lisa,Shu, Arthur,Votta, Bartholomew J.,Zhou, Huiqiang,Bertin, John,Marquis, Robert W.
supporting information, p. 1518 - 1523 (2019/10/19)
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.
Synthesis of Aryl Hydrazines via CuI/BMPO Catalyzed Cross-Coupling of Aryl Halides with Hydrazine Hydrate in Water
Kumar, Siripuram Vijay,Ma, Dawei
supporting information, p. 1003 - 1006 (2018/09/20)
The N,N’-bis(2,6-dimethylphenyl)oxalamide was discovered as a powerful ligand for Cu-catalyzed cross-coupling of aryl halides with hydrazine hydrate, leading to the formation of a variety of aryl hydrazines at 80 oC in water under the assistance of K3PO4 and 4 mol% cetyltrimethylammonium bromide from aryl bromides and aryl iodides. Good to excellent yields were observed in most cases.
Pyrazole compounds as sigma receptor inhibitors
-
Page/Page column 12; 17-18, (2012/01/03)
The invention refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.
